Cotización ObsEva - OBSV

Mejore su cartera: debates en tiempo real e ideas comerciales prácticas.

Premium

Último Precio

0.1018

Postura de Compra

0.1017

Postura de Venta

0.106

Volume Operado de la Acción

0.00 Rango del Día 0.00

0.1018 Rango de 52 semanas 0.1018

Capitalización de Mercado [m]

8.139M

Precio Anterior

0.1018

Precio de Apertura

Hora

Última hora de negociación

Volumen financiero

Precio Promedio Ponderado

Volumen promedio (3 m)

Acciones en circulación

79,955,268

Rendimiento del Dividendo

Ratio Precio/Utilidad

-0.27

Beneficio por acción (BPA)

-0.37

turnover

19.64M

Beneficio neto

-29.88M

Sector

Biological Pds,ex Diagnstics

Industria

Biological Pds,ex Diagnstics

Sitio web

www.obseva.com

Sede

Geneva, Che

Fundado

ObsEva SA is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker OBSV. The last closing price for ObsEva was US$0.10. Over the last year, ObsEva shares have traded in a share price range of US$ 0.1018 to US$ 0.1018.

ObsEva currently has 79,955,268 shares in issue. The market capitalisation of ObsEva is US$8.14 million. ObsEva has a price to earnings ratio (PE ratio) of -0.27.

ObsEva Announces Delisting from SIX Swiss Exchange and Exemption from Certain Obligations Associated with the Maintenance of Listin

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – April 3, 2024 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing and commercializing novel...

ObsEva Announces Update on Board of Directors

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – March 18, 2024 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing and commercializing novel...

ObsEva Announces Wind-Down of Operations and Notifies SIX that it Will Lack the Resources to Establish Audited IFRS Financial Statements for 2023

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland – 28 February 2024 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing novel therapies for...

Geneva Court Grants Temporary Moratorium to ObsEva

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland – 31 January 2024 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing novel therapies for...

ObsEva Announces Application for a Moratorium to Facilitate Pivotal Deals

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland – November 30, 2023 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing novel therapies for...

Organon Returns Ebopiprant to XOMA

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland – October 27, 2023 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing novel therapies for...

ObsEva Files half Year 2023 Financial Statements

ObsEva Files half Year 2023 Financial Statements Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland – September 27, 2023 – ObsEva SA (SIX: OBSN), a...

ObsEva Recovers Full Worldwide Rights on Nolasiban

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland – July 13, 2023 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing novel therapies for women's...

Annual General Meeting 2023

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland – June 8, 2023 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing novel therapies for women's...

ObsEva Appoints Fabien de Ladonchamps as Chief Executive Officer

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – May 2, 2023 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing novel therapies for women’s...

ObsEva Announces Delisting from SIX Swiss Exchange and Exemption from Certain Obligations Associated with the Maintenance of Listin

ObsEva Announces Update on Board of Directors

ObsEva Announces Wind-Down of Operations and Notifies SIX that it Will Lack the Resources to Establish Audited IFRS Financial Statements for 2023

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland – 28 February 2024 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing novel therapies for...

Período †	Variación(Ptos)	Variación %	Apertura	Precio Máximo	Precio Mínimo	Avg. Vol. diario	Precio Promedio Ponderado
1	0	0	0.1018	0.1018	0.1018	0	0	CS
4	0	0	0.1018	0.1018	0.1018	0	0	CS
12	0	0	0.1018	0.1018	0.1018	0	0	CS
26	0	0	0.1018	0.1018	0.1018	0	0	CS
52	0	0	0.1018	0.1018	0.1018	0	0	CS
156	-3.0972	-96.8177555486	3.199	3.27	0.08	1538109	0.42043651	CS
260	-9.0482	-98.887431694	9.15	9.62	0.08	1537373	1.66253829	CS

Volumen
% Mayores Alzas
% Mayores Bajas

Símbolo	Precio	Vol.
XPONExpion360 Inc	US$ 0.1278 (119.59%)	171.76M
LFLYLeafly Holdings Inc	US$ 3.26 (82.12%)	4.61M
BNZIBanzai International Inc	US$ 4.89 (69.79%)	6.36M
TNONTenon Medical Inc	US$ 6.64 (32.01%)	4.05M
GDHGGolden Heaven Group Holdings Ltd	US$ 3.96 (28.57%)	5.74M
KOPNKopin Corporation	US$ 0.68 (-29.47%)	743.26k
BFIBurgerFi International Inc	US$ 0.11 (-25.73%)	981.92k
NVECNVE Corporation	US$ 60.00 (-24.23%)	57
TOMZTOMI Environmental Solutions Inc	US$ 0.585 (-23.03%)	1.06k
MOVEMovano Inc	US$ 0.291 (-19.41%)	1,000
XPONExpion360 Inc	US$ 0.1274 (118.90%)	171.96M
SVMHSRIVARU Holding Ltd	US$ 0.1577 (27.18%)	41.67M
AKTSAkoustis Technologies Inc	US$ 0.07 (2.79%)	16.34M
RRRichtech Robotics Inc	US$ 0.9605 (4.12%)	9.3M
SQQQProShares UltraPro Short QQQ	US$ 7.78 (0.26%)	6.45M